Clinical study of Bufei-Huayu-Tongluo Decoction and western medicine for chronic pulmonary embolism
10.3760/cma.j.cn115398-20200321-00258
- VernacularTitle:补肺化瘀通络汤结合西医常规疗法治疗慢性肺栓塞临床研究
- Author:
Wen ZHANG
1
;
Qinghong YAN
Author Information
1. 山东省济宁医学院附属湖西医院（单县中心医院）老年医学科 274300
- Keywords:
Pulmonary embolism;
Chronic disease;
Bufei-Huayu-Tongluo Decoction;
High mobility group proteinB1;
D-dimer
- From:
International Journal of Traditional Chinese Medicine
2021;43(8):763-766
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical effect of Bufei-Huayu-Tongluo decoction combined with western medicine on chronic pulmonary embolism (PE). Methods:A total of 120 patients with chronic PE, who met the inclusion criteria in our hospital from January 2016 to May 2019, were randomly divided into two groups, 60 cases in each group. The control group was given conventional western medicine treatment, and the study group was given Bufei-Huayu-Tongluo Decoction on the basis of the control group. Both groups were treated for 4 weeks. The forced expiratory volume in one second (FVE1) and forced vital capacity (FVC) were measured by pulmonary function analyzer; the fibrinogen (FIB) and prothrombin time (PT) were detected by coagulation analyzer; and D-dimer was detected by immunoturbidimetry; high mobility group protein B1 (HMGB-1), troponin (cTnI) were detected by ELISA, adverse reactions were recorded and clinical efficacy was evaluated. Results:The total effective rate of the study group was 93.3% (56/60) and that of the control group was 78.3% (47/60). The difference between the two groups was statistically significant ( χ2=5.551, P=0.018). After treatment, FVE1 (1.74 ± 0.26 L vs. 1.55 ± 0.29 L, t=3.779), FVC (66.73% ± 7.54% vs. 58.69% ± 6.32%, t=6.330) in the study group were significantly higher than those in the control group ( P<0.01); serum FIB level (2.85 ± 0.30 g/L vs. 2.36 ± 0.31 g/L, t=8.798), PT (15.31 ± 0.73 s vs. 11.27 ± 0.52 s, t=34.915) were significantly higher than those in the control group ( P<0.01); serum D-dimer (0.66 ± 0.23 mg/L vs. 1.18 ± 0.32 mg/L, t=9.447), HMGB-1 (3.59 ± 0.75 μg/L vs. 6.14 ± 1.28 μg/L, t=13.280) and cTnI (0.62 ± 0.26 μg/L vs. 1.02 ± 0.26 μg/L, t=8.896) were significantly lower than those in the control group ( P<0.01). During the treatment, the incidence of adverse reactions in the control group was 13.3% (8/60) and that in the study group was 15.0% (9/60). There was no significant difference between the two groups ( χ2=0.069, P=0.793). Conclusion:Bufei-Huayu-Tongluo Decoction combined with conventional western medicine therapy can improve lung function and coagulation function of patients with chronic PE.
